Precision Biosciences Has Received A Notice Of Allowance From The U.S. Patent And Trademark Office Related To Engineered Meganucleases That Target Human Mitochondrial Genomes, Once Issued, The Patent Expiry Stands At April 2024
Portfolio Pulse from Benzinga Newsdesk
Precision Biosciences has received a notice of allowance from the U.S. Patent and Trademark Office for engineered meganucleases that target human mitochondrial genomes. The patent, once issued, will expire in April 2024.
September 27, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precision Biosciences' patent approval could potentially boost its competitive advantage in the biotech industry, at least until the patent expires in 2024.
The approval of a new patent typically strengthens a company's position in the market, potentially leading to increased investor confidence and a positive impact on the stock price. However, the impact may be limited by the relatively short duration of the patent, which expires in 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100